J. Grem, M. Kos, R. Evande
Nov 1, 2015
Citations
0
Influential Citations
2
Citations
Journal
Cancer
Abstract
Pralatrexate (PDX) is an inhibitor of dihydrofolate reductase that was rationally designed to improve cellular uptake and retention of the drug. Preclinical data have shown synergy with the sequential administration of a dihydrofolate reductase inhibitor followed 24 hours later by 5‐fluorouracil (5‐FU).